Navigation Links
AGA Medical Corporation Agrees to Pay $2 Million Penalty and Enter Deferred Prosecution Agreement for FCPA Violations
Date:6/3/2008

WASHINGTON, June 3 /PRNewswire-USNewswire/ -- AGA Medical Corporation (AGA), a privately-held medical device manufacturer, has agreed to pay a $2 million criminal penalty in connection with corrupt payments to Chinese government officials in violation of the Foreign Corrupt Practices Act (FCPA), Acting Assistant Attorney General Matthew Friedrich announced today.

The Department entered into a deferred prosecution agreement with AGA and filed a criminal information against the company in the U.S. District Court for the District of Minnesota. AGA, incorporated and headquartered in Minnesota, specializes in the manufacture of products designed for the minimally invasive treatment of congenital heart defects. The two-count criminal information charges AGA with one count of conspiring to make bribe payments to Chinese officials and one count of violating the FCPA in connection with the authorization of specific corrupt payments to officials in China.

According to the criminal information, between 1997 and 2005, AGA, a high-ranking officer of AGA and other AGA employees agreed to make corrupt payments to doctors in China who were employed by government-owned hospitals and caused those payments to be made through AGA's local Chinese distributor. In exchange for these payments, the Chinese doctors directed the government-owned hospitals to purchase AGA's products rather than those of the company's competitors.

The criminal information also alleges that from 2000 through 2002, AGA sought patents on several AGA products from the People's Republic of China State Intellectual Property Office. As a part of this effort, AGA and a high-ranking officer of AGA agreed to make payments through their local Chinese distributor to Chinese government officials employed by the State Intellectual Property Office in order to have the patents approved.

In recognition of AGA's voluntary disclosure and thorough review of the improper payments, its cooperation with the Department's investigation, the company's implementation of enhanced compliance policies and procedures, and the company's engagement of an independent corporate monitor, the Department has agreed to defer prosecution of AGA for three years. If AGA abides by the terms of the agreement, the Department will dismiss the criminal information when the term of the agreement ends.

This case is being prosecuted by Trial Attorney David Bybee and Assistant Chief William B. Jacobson of the Criminal Division's Fraud Section and is being investigated by the Minneapolis, Minn., FBI field office.


'/>"/>
SOURCE U.S. Department of Justice
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 132 Members of Congress Urge One-Year Delay in Controversial Medicare Bidding Program for Home Medical Equipment
2. Blue Cross Blue Shield of Michigan Forum Examines Cutting-Edge Medical Care That Better Meets Patients Needs
3. China Sky One Medical, Inc. Receives SFDA Approval for Five Patches
4. AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an A
5. Association of Medical Illustrators Denounces Orphan Works Bills Before Congress
6. University of Tennessee Medical Center Initiates Patient-Specific Medication Management With SinglePointe(TM) Solution From Omnicell
7. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor
8. ReBuilder Medical Technologies, Inc. Appears Recession Proof
9. Dawning Technologies, Inc. and Medical Automation Systems, Inc. to Develop a Business Partnership
10. Medical Simulation Corporation Announces Partnership With Seattle Science Foundation
11. Valley Forge Medical Center and Hospital to Become the First Addiction-Free Pain Management Center of Excellence on the East Coast; Will Host Three Day Professional Training Seminar.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: